Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis

Armağan, Berkan; Kılıç, Levent; Farisoğullari, B.; Yardimci, G. K.; Bılgın, Emre; Bolek, E. C.; Karadağ, Ömer; Bilgen, Şule Apraş; Kiraz, Sedat; Ertenli, İhsan; Kalyoncu, Umut

doi:10.1007/s00296-022-05213-1

Cited by 9 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug retention rate of IL-17is observed in our study was similar to that of secukinumab reported in European populations (1-year, 55%–72%; 2-year, 43%–61%). 16 17 18 19 Considering that all patients in our study received IL-17is as a second- or later-line bDMARD, whereas in the European studies a proportion of patients (8.0%–30.8%) received secukinumab as a first-line bDMARD, 16 17 18 19 the similar drug retention rate observed in our study is encouraging. Moreover, the drug retention rate of IL-17is in our study was also similar to that of TNFis used as first-line bDMARD (1-year, 74%–76%; 2-year, 63%–65%), 13 14 suggesting that IL-17is could be a good therapeutic option even as a later-line bDMARD.…”

Section: Discussionsupporting

confidence: 81%

“… 31 Together, these suggest IL-17 as a key pathogenic cytokine in obese patients, possibly explaining the lower risk of discontinuation of secukinumab in obese patients observed in previous studies. 17 19 However, in our study, BMI was not associated with the risk of IL-17is discontinuation (unadjusted HR=0.995, 95% CI=0.913–1.083, p =0.901). When interpreting our data, it should be considered that in the previous studies that reported the association between obesity and lower risk of discontinuation of secukinumab, the cut-off BMI for obesity was 30 kg/m 2 .…”

Section: Discussioncontrasting

confidence: 67%

“…Obesity has been suggested as a factor associated with a favorable drug retention rate of secukinumab. 17 19 Obesity promotes the expansion of IL-17-producing T cells in peripheral tissues. 30 Moreover, compared with nonobese individuals, obese individuals have higher serum levels of IL-17.…”

Section: Discussionmentioning

confidence: 99%

“…The reported 1-year and 2-year drug retention rates of secukinumab are 55%–72% and 43%–61%, respectively. 16 17 18 19 However, data on the drug retention rates of IL-17is when used only as second- or later-line bDMARD (as in the setting of South Korea) are scarce. Although a study from Korea reported a 1-year drug retention rate of 75% for secukinumab, 20 long-term data are limited.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis

Kwon,

Park

2023

Yonsei Med J

View full text Add to dashboard Cite

Purpose To assess the drug retention rate of interleukin-17 inhibitors (IL-17is) over long-term observation in patients with axial spondyloarthritis (axSpA) in whom treatment with tumor necrosis factor inhibitors (TNFis) failed and to determine baseline factors associated with discontinuation of IL-17is. Materials and Methods This retrospective cohort study included 68 patients with axSpA started on IL-17is after an inadequate response or intolerance to ≥1 TNFis. Drug retention rates at 1, 2, and 3 years were assessed. Baseline (i.e., at initiation of IL-17is) factors associated with discontinuation of IL-17is were evaluated using multivariable Cox proportional hazard regression analysis. Results Over 1933.9 person-months of observation in 68 patients, discontinuation of IL-17is occurred in 27 (39.7%) patients. Twenty (29.4%) patients discontinued IL-17is because of ineffectiveness, and 7 (10.3%) patients discontinued IL-17is because of adverse events. The 1-year, 2-year, and 3-year drug retention rates for IL-17is were 71.9%, 66.5%, and 62.0%, respectively. Current smoking was associated with a higher risk of IL-17is discontinuation [adjusted hazard ratio (HR)=2.256, 95% confidence interval (CI)=1.053–4.831, p =0.036], while previous use of ≥3 TNFis (vs. 1) was significantly associated with a lower risk of IL-17is discontinuation (adjusted HR=0.223, 95% CI=0.051–0.969, p =0.045). Conclusion In patients with axSpA in whom TNFis failed, the long-term drug retention rate of IL-17is appears to be acceptable, with a 3-year drug retention rate of approximately 60%. Current smoking was associated with a higher risk of discontinuing IL-17is, whereas previous use of ≥3 TNFis was associated with a lower risk of discontinuing IL-17is.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussioncontrasting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis

Kwon,

Park

2023

Yonsei Med J

View full text Add to dashboard Cite

show abstract

“…Several factors indicated as predictors of anti-TNF therapy retention, such as BMI and smoking status, could not be included in the multivariate Cox regression analysis because >20% of the data were missing. The high percentage of missing data concerning obesity and smoking could be also considered as a weakness of the study since these two patients’ characteristics (and in particular obesity) have been previously reported as predisposing factors of IL-17 retention rate in axSpA with conflicting results: obesity associated with a longer 44 or a shorter retention rate. It is obviously important to check whether there is a difference in the predisposing factors of drug retention rate based on their mechanism of action to potentially guide the choice of the drug (IL17 vs TNF inhibitors) to use as the first biotherapy in daily practice.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

Dougados

Lucas²,

Desfleurs

et al. 2023

RMD Open

View full text Add to dashboard Cite

BackgroundSecukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention rate. The key objective was to determine whether objective signs of inflammation (OSI) were predictive of secukinumab retention at 1 year.MethodsFORSYA is a French, multicentric, non-interventional, retrospective study in adult axSpA patients who received secukinumab treatment between its launch (11 August 2016) and 31 August 2018. The time to secukinumab discontinuation and retention were analysed using a Kaplan-Meier (KM) analysis. OSI was predefined by at least one of the criteria: C reactive protein ≥5 mg/L or erythrocyte sedimentation rate ≥28 mm/hour at secukinumab initiation or MRI inflammation at the sacroiliac or spine level.ResultsIn total, 906 patients from 48 centres were included in the analysis, 42.2% of whom were men, with a mean age of 46.2±11.7 years and a mean disease duration of 9.3±9.1 years. The 1-year KM retention rate (95% CI) for secukinumab was 59% (55%–62%), whereas for patients with and without OSI, it was 58% (54%–62%) and 63% (53%–73%), respectively. In multivariate analysis, lack of prior exposure to tumour necrosis factor inhibitor (TNFi), absence of OSI and inflammatory bowel disease (IBD) were associated with a better retention of secukinumab at 1 year.ConclusionFollowing its approval in France, ~59% of axSpA patients retained secukinumab in daily practice, at 1 year. Prior exposure to TNFi, OSI and IBD were identified as risk factors for secukinumab discontinuation.

show abstract

Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review

Gialouri

Παππά

Evangelatos

et al. 2023

Autoimmunity Reviews

View full text Add to dashboard Cite

Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis

Cited by 9 publications

References 36 publications

Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis

Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review

Contact Info

Product

Resources

About